Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Eur Radiol. 2022 Jan 31;32(7):4967–4979. doi: 10.1007/s00330-021-08529-x

Fig. 3.

Fig. 3.

Quantitative evaluation of the tumor-to-marrow contrast on 2-[18F]FDG-PET and DW-MRI scans. a 2-[18F]FDG-PET: Standardized uptake values (SUV) of bone marrow metastases (SUVmax) are significantly higher compared to SUVmean of normal bone marrow on baseline and post-treatment scans (p< 0.001, respectively). b DW-MRI: Signal-to-noise ratios (SNR) of bone marrow metastases (tumor) are significantly higher compared to SNR of normal bone marrow on baseline and post-treatment scans (p< 0.001, respectively). c The tumor-to-marrow contrast on 2-[18F]FDG-PET, measured as the difference between the tumor SUVmax and normal bone marrow SUVmean, was significantly smaller on post-treatment scans compared to baseline scans (p=0.014). The tumor-to-marrow contrast on DW-MRI, measured as the difference between the tumor SNR and normal bone marrow SNR, was not statistically significant between baseline and post-treatment scans (p=0.118). Baseline data are displayed as mean values of 62 true positive lesions on 2-[18F]FDG-PET and 57 true positive lesions on DW-MRI plus standard deviations. Post-treatment data are displayed as mean values of 139 true positive lesions on 2-[18F]FDG-PET and 140 true positive lesions on DW-MRI plus standard deviations.